bioMérieux : Feedback CMD : la feuille de route moyen terme si situerait plutôt au-dessus ou dans le haut des attentes du css
>Un plan de croissance du CA à +7%/an et +10% pour le cEBIT - bioMérieux a tenu hier son CMD. Le management a présenté une feuille de route à horizon 2028. Dans son Plan à 5 ans (Plan GO 2028) BIM prévoit notamment i/ une croissance du CA de 7%/an (TMVA 2024-28e), ii/ une MOp. de 20% en 2028 (vs 16,1% en 2024 et env. 17,3%e hors FX qui sera défavorable ), soit un gain de MOp. de 340 pb entre 2023 et 2028, iii/ un plan de Capex de 8-10% du CA/an (maintien en raison des...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.